Andrew Tepe
Family Medicine · Blanchester, OHNPI 1972087724
Payments from drug & device makers
Across 488 payments — averaging $15.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Teva Pharmaceuticals USA, Inc.$652
- Novo Nordisk$538
- AstraZeneca$444
- Lilly USA, LLC$382
- Johnson & Johnson$289
- plus $3K from 45 others
What the payments were for
- Food & beverage$7,21296%
- Education$2644%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,476 in reported general payments places this provider in the 90th percentile of 3,983 family medicine providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 72 | $106,038 |
| FarxigaDapagliflozin Propanediol | 56 | $61,212 |
| TrulicityDulaglutide | 47 | $50,783 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 60 | $44,849 |
| JardianceEmpagliflozin | 34 | $39,160 |
| EliquisApixaban | 35 | $34,998 |
| Nurtec OdtRimegepant Sulfate | 16 | $29,494 |
| KerendiaFinerenone | 20 | $19,376 |
| XareltoRivaroxaban | 22 | $18,684 |
| VascepaIcosapent Ethyl | 31 | $15,921 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $15,342 |
| Repatha SureclickEvolocumab | 17 | $14,678 |
| MounjaroTirzepatide | 13 | $13,477 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 13 | $10,422 |
| MyrbetriqMirabegron | 15 | $9,262 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $538 | $106,03872 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $444 | $81,53695 claims |
| PfizerEliquis, Nurtec Odt | $196 | $64,49251 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $382 | $64,26060 claims |
| GSKTrelegy Ellipta | $43 | $44,84960 claims |
| Boehringer IngelheimJardiance | $100 | $39,16034 claims |
| BayerKerendia | $98 | $19,37620 claims |
| Johnson & JohnsonXarelto | $289 | $18,68422 claims |
| MerckJanumet Xr | $39 | $10,42213 claims |
| Astellas Pharma US IncMyrbetriq | $116 | $9,26215 claims |
| AbbVieSynthroid | $2,058 | $3,51434 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Blanchester
- Catherine LaruffaBlanchester$77K
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.